San Francisco, California, March 29, 2018 – The global hospital-acquired disease testing market is envisioned to be boosted with the alarming increase in hospital-acquired infections (HAIs) and tight government regulations that penalize healthcare centers with high HAI rates. A report by TMR Research offers a comprehensive evaluation of the market based on various factors. It is titled “Hospital Acquired Disease Testing Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025.” Urinary tract infection (UTI) affecting several individuals across the world could be one of the most common HAIs securing a prominent share of the market. However, hospital-acquired disease testing could also be largely used for surgical site, methicillin-resistant staphylococcus aureus (MRSA), and pneumonia infections.
Followed by Europe, North America is prophesied to take hold of a handsome share of the world hospital-acquired disease testing market. This region could bank on the growing frequency of HAIs causing increasing annual death incidences in the U.S. The growth of the regional market is foretold to be fueled with the swelling demand for diagnostics and regulations implemented by government bodies. However, the market could witness the faster growth of Asia Pacific in the coming years. Increasing regulations of Asia Pacific governments to reduce the incidence of HAI and rising prevalence of nosocomial infections are prognosticated to support the growth of the regional market.
Get Sample Copy of this Report @
The international hospital-acquired disease testing market is projected to offer little scope for emerging companies to make an entry. The vendor landscape of the market could uphold an intensified level of competition due to the tremendously limited number of companies operating in the industry. Companies could look to explore emerging markets and vast prospects existing therein. Some of the top players of the market are Alere, Inc., Becton Dickinson and Company, Thermo Fisher Scientific, Inc., Abbott Laboratories, and Roche.